Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in RA Patients with Inadequate Response to Anti-TNF Agents
NCT01770379Phase 3Terminated
- Sponsor
- Novartis
- Start
- Oct 2012
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of secukinumab in rheumatoid arthritis (RA), sponsored by Novartis. Started Oct 2012; status: terminated.
02
Drugs
secukinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01770379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01770379.